Drug Profile
Epirubicin companion diagnostic - Allarity Therapeutics
Alternative Names: Epirubicin DRPLatest Information Update: 28 Oct 2020
Price :
$50
*
At a glance
- Originator Medical Prognosis Institute
- Developer Allarity Therapeutics
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 26 Oct 2020 Allarity Therapeutics receives patent allowance from the USPTO for Methods for predicting drug responsiveness in Cancer in the US
- 07 Oct 2020 Oncology Venture A/S is now called Allarity Therapeutics
- 28 Jun 2020 No recent reports of development identified for clinical-Phase-Unknown development in Breast-cancer(Diagnosis) in Denmark